GLAXO2021-07-012021-09-30in-bse-fin:OneOperatingExpenses01Member GLAXO2021-07-012021-09-30in-bse-fin:FourOperatingExpenses01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares GLAXO 2021-04-01 2022-03-31 2021-09-27 INR Lakhs Half yearly true Cash Flow Indirect Single segment Pharmaceuticals 2021-07-01 2021-09-30 Unaudited Standalone 9915300000.00 150500000.00 10065800000.00 1451100000.00 2206200000.00 178400000.00 1600100000.00 3500000.00 176000000.00 1735600000.00 7350900000.00 2714900000.00 0.00 2714900000.00 726200000.00 -37800000.00 688400000.00 0.00 2026500000.00 0.00 0.00 0.00 0.00 2026500000.00 0.00 2026500000.00 0.00 0.00 1694100000.00 10 11.96 11.96 0.00 0.00 11.96 11.96 1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 29th October, 2021. 2. In accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, the Statutory Auditors have carried out a limited review of the standalone financial results for the quarter and six months ended 30th September, 2021. 3. Other income for the quarter ended 30th September 2021 and 30th June 2021 includes interest on income tax refund of Rs.562 Lakhs and Rs. 2121 Lakhs respectively (six months ended ended 30th September 2020 Rs. 4268 Lakhs), year ended 31st March 2021 Rs.7129 lakhs respectively. 4. Exceptional items for the quarter ended 30th September, 2020 of Rs.6413 Lakhs mainly comprise of: Impact following the decision to initiate a global voluntary recall (pharmacy/retail level) of ranitidine products including Zinetac in India by the Ultimate Holding Company, a comprehensive strategic review of the impact of this recall was undertaken by the Company on all related assets in India including its manufacturing site at Vemgal. After considering all the strategic options available, the Company during the quarter had decided to proceed with the sale of the site and had classified the assets as held for sale. Consequently, the company had recognized financial impact of INR 6413 lakhs to reflect the estimated realizable value of the assets, associated costs and impacts of reversal of provision on account of Zinetac recall. 5. Transfer of the trademarks pertaining to ‘Iodex’ and ‘Ostocalcium’ brands in India to GlaxoSmithKline Asia Private Limited has been approved by the shareholders and is further subject to customary regulatory approvals. Consequently no effect has been given in this financial results for the proposed transaction. 6. Consequent to the approval of the shareholders, the company on 30th September, 2021, has acquired the assets and liabilities associated with the vaccine business of GSK Asia. The company has accounted the acquisition in accordance with Appendix C to IND AS 103 being business combination of entities under common control. Accordingly, the financial information in respect of prior periods has been restated for the acquisition as if the business combination had occurred from the beginning of preceding periods. The difference between the consideration paid/ payable and the net assets on acquisition of Rs. 2082 Lakhs has been transferred to Capital reserve. 7. The spread of Covid-19 is having an unprecedented impact on people and economy. The Company has considered the possible effects that may result from the pandemic relating to COVID-19 on the carrying amounts of trade receivables, tangible assets, intangible assets and investments. In developing the assumptions relating to the possible future uncertainties in the economic conditions because of this pandemic, the Company, as at the date of approval of these financial results has used internal and external sources of information. The impact assessment of Covid-19 is a continuing process given the uncertainties and the Company will continue to closely monitor the developments. 8. Dividend of Rs. 50822 Lakhs has been paid during the current quarter ended 30th September, 2021 consequent to the Board of Directors declaring dividend of Rs. 30 per equity share for the year ended 31st March, 2021 which had been approved by the shareholders in the Annual General meeting held on 27th July, 2021. 9. The Company has only one reportable segment which is Pharmaceuticals. Accordingly, no separate disclosures of segment information have been made. 10. Previous periods' figures have been re-grouped / re-classified wherever necessary. Single segment 2021-04-01 2021-09-30 Unaudited Standalone 17649900000.00 467800000.00 18117700000.00 3122500000.00 3619100000.00 42500000.00 3278000000.00 11400000.00 353100000.00 3337000000.00 13763600000.00 4354100000.00 0.00 4354100000.00 1196200000.00 -72600000.00 1123600000.00 0.00 3230500000.00 0.00 0.00 0.00 0.00 3230500000.00 0.00 3230500000.00 0.00 0.00 1694100000.00 10 19.07 19.07 0.00 0.00 19.07 19.07 Other Expenses 1735600000.00 Other Expenses 3337000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -100500000.00 0.00 -100500000.00 4253600000.00 0.00 0.00 0.00 0.00 1005100000.00 5258700000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1744400000.00 0.00 1744400000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -5170900000.00 -5170900000.00 1832200000.00 0.00 1832200000.00 4049000000.00 5881200000.00